Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsSierra Health and Life Veopoz Coverage Update | Op…
    Ask Trek AI about this page
    Currentsierra health and lifePolicy 2026D0128E

    Veopoz (pozelimab‑bbfg) — Medical Benefit Coverage Criteria for CD55‑deficient PLE (CHAPLE)

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026D0128E alerts

    Get alerted when Policy 2026D0128E changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical benefit coverage and prior authorization criteria for Veopoz (pozelimab‑bbfg) for members on UnitedHealthcare Commercial and Individual Exchange plans for treatment of CD55‑deficient protein‑losing enteropathy (PLE/CHAPLE). It applies to providers seeking coverage under those plans.

    Policy Summary
    Payersierra health and life
    PolicyVeopoz (pozelimab‑bbfg) — Coverage Criteria
    Policy CodePolicy 2026D0128E
    Change TypeNo material change
    Effective DateMay 1, 2026
    Next Review Date
    Key ActionObtain prior authorization with genetic confirmation of a biallelic CD55 loss‑of‑function mutation and documentation of CHAPLE signs/symptoms.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1FDA‑approved indication (age ≥1 year)
    J9376

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    HCPCS code
    12Max initial authorization (months)
    10Patients in pivotal study
    15.5 daysEfficacy endpoint (median)

    Coverage criteria and usage restrictions

    Initial Therapy — Veopoz

    Veopoz is medically necessary when ALL of the following are met for initial therapy:

    Initial Therapy Criteria: Diagnosis of CD55‑deficient PLE (CHAPLE) or CD55 deficiency with complement hyperactivation, angiopathic thrombosis, protein‑losing enteropathy; AND submission of medical records (e.g., chart notes, laboratory values) confirming a biallelic loss‑of‑function mutation in the CD55 gene; AND laboratory results, signs, or symptoms attributable to CHAPLE disease (e.g., hypoalbuminemia, peripheral or facial edema, abdominal pain, diarrhea); AND patient is not receiving Veopoz in combination with another complement protein C5 inhibitor (e.g., eculizumab, ravulizumab) for CHAPLE; AND dosing is in accordance with the U.S. FDA approved labeling; AND prescribed by a hematologist or other specialist with expertise in CHAPLE; AND initial authorization will be for no more than 12 months

    Continuation Therapy — Veopoz

    Continuation of therapy is covered when ALL of the following are met:

    Continuation Criteria: Documentation demonstrating a positive clinical response from baseline (examples: normalization of serum albumin, reduction of peripheral or facial edema, reduction in abdominal pain or diarrhea); AND patient is not receiving Veopoz in combination with another complement protein C5 inhibitor (e.g., eculizumab, ravulizumab) for CHAPLE; AND dosing is in accordance with the U.S. FDA approved labeling; AND prescribed by a hematologist or other specialist with expertise in CHAPLE

    Use of other complement protein C5 inhibitors is specifically prohibited during treatment for CHAPLE disease. The policy requires that the patient not be receiving Veopoz in combination with another complement C5 inhibitor (for example, eculizumab or ravulizumab) as a condition of both initial and continuation authorization.

    This prohibition appears in the initial authorization criteria and in the continuation criteria and is a trigger for denial if documentation shows concomitant therapy with another C5 inhibitor.

    This policy does not authorize broad off‑label or investigational use of Veopoz. Coverage decisions for off‑label or experimental indications depend on the member’s specific benefit plan and any applicable state mandates; the member’s Certificate of Coverage and plan language must be consulted to determine whether such uses may be covered.

    Veopoz is FDA‑approved for treatment of CD55‑deficient protein‑losing enteropathy (PLE) (CHAPLE disease) in patients aged 1 year and older, but FDA approval alone does not guarantee coverage—coverage is determined by the plan and policy criteria described here.

    Billing and diagnosis codes

    HCPCS CodesHCPCS
    J9376Injection, pozelimab-bbfg, 1 mg
    Diagnosis Codes (example)ICD-10
    D84.1Defects in the complement system
    inv-07: Active disease albumin threshold — serum albumin ≤ 3.2 g/dL
    Albumin thresholdSerum albumin concentration ≤ 3.2 g/dL
    Context for thresholdDefined for active CD55‑deficient PLE used to identify patients with hypoalbuminemia in the pivotal study
    Timeframe for symptomsAssociated signs or symptoms within the last six months (e.g., abdominal pain, diarrhea, peripheral or facial edema)
    BasisThreshold derived from clinical trial inclusion criteria and efficacy assessments

    Prior authorization, documentation, and denial triggers

    Prior Authorization

    Obtain prior authorization with genetic and clinical confirmation

    Prior authorization is required and must document: diagnosis of CD55‑deficient PLE (CHAPLE) or CD55 deficiency with complement hyperactivation/angiopathic thrombosis/protein‑losing enteropathy; submission of medical records confirming a biallelic loss‑of‑function mutation in CD55; laboratory results, signs, or symptoms attributable to CHAPLE (for example hypoalbuminemia, peripheral or facial edema, abdominal pain, diarrhea); that the patient is not receiving Veopoz in combination with another complement C5 inhibitor; dosing per FDA‑approved labeling; prescribed by a hematologist or other specialist with CHAPLE expertise; and initial authorization limited to no more than 12 months.

    • Diagnosis of CD55‑deficient PLE or CD55 deficiency with complement hyperactivation, angiopathic thrombosis, protein‑losing enteropathy
    • Medical records confirming a biallelic loss‑of‑function mutation in CD55
    • Laboratory results, signs, or symptoms attributable to CHAPLE (e.g., hypoalbuminemia, edema, abdominal pain, diarrhea)
    • Confirmation patient is not receiving Veopoz with another complement C5 inhibitor (e.g., eculizumab, ravulizumab)
    • Dosing consistent with FDA labeling
    • Prescribed by a hematologist or specialist with CHAPLE expertise
    • Initial authorization limited to up to 12 months

    Initial authorization criteria

    Initial Therapy — Authorization Criteria & Limitations

    Initial authorization criteria and limitations for Veopoz:

    Initial Authorization: Confirmed diagnosis of CD55‑deficient PLE/CHAPLE; genetic confirmation with submission of medical records showing a biallelic loss‑of‑function CD55 mutation; clinical signs/symptoms attributable to CHAPLE (e.g., hypoalbuminemia, edema, abdominal pain, diarrhea); no concomitant use with another C5 inhibitor for CHAPLE; dosing per U.S. FDA labeling; prescribed by a hematologist or specialist with CHAPLE expertise; initial authorization limited to up to 12 months

    Criteria for continued coverage

    Continuation Therapy — Requirements

    Continuation requires documented clinical benefit and the same restrictions as initial therapy:

    Continuation Requirements: Documented positive clinical response from baseline (examples: normalization of serum albumin, reduction of edema, reduction in abdominal pain or diarrhea); no concomitant use with another complement protein C5 inhibitor for CHAPLE; dosing per U.S. FDA labeling; prescribed by a hematologist or other specialist with CHAPLE expertise

    Step therapy and prerequisites

    StepRequirement
    {"text":"1","status":""}|{"text":"No step-therapy requirement specified; initiation requires genetic confirmation of a biallelic loss-of-function CD55 mutation and documentation of diagnosis of CD55‑deficient PLE (CHAPLE) with laboratory results, signs/symptoms attributable to CHAPLE, dosing per FDA labeling, and prescribed by a hematologist or other specialist with CHAPLE expertise; initial authorization limited to up to 12 months.","status":""}
    {"text":"Concomitant Therapy","status":""}|{"text":"Concomitant use of Veopoz with another complement protein C5 inhibitor (e.g., eculizumab, ravulizumab/Ultomiris) for treatment of CHAPLE is not allowed.","status":"not_covered"}

    Administration site considerations

    Note

    No site‑of‑care limits here — consult Site of Care policy and plan

    This policy does not impose site‑of‑care specific limits for infusion centers; consult the related Provider Administered Drugs - Site of Care policy and the member’s benefit plan for any site‑of‑care rules that may apply.

    • No site‑of‑care specific limits stated in this policy (chunk 6).
    • Refer to Provider Administered Drugs - Site of Care policy and member specific benefit plan for applicable rules (chunk 15).

    Definitions used in this policy

    inv-13: Active CD55-deficient PLE — hypoalbuminemia (serum albumin ≤ 3.2 g/dL) with associated GI symptoms
    DefinitionHypoalbuminemia: serum albumin concentration ≤ 3.2 g/dL with one or more associated GI or edema symptoms
    Associated symptomsOne or more of abdominal pain, diarrhea, peripheral edema, or facial edema within the last six months
    Diagnostic confirmationDiagnosis based on clinical history of PLE with confirmed biallelic CD55 loss‑of‑function mutation
    Clinical useThreshold and symptom combination used to define 'active' disease for eligibility and efficacy assessment in the Veopoz study

    Clinical background

    CD55‑deficient protein‑losing enteropathy (CHAPLE) is caused by biallelic loss‑of‑function mutations in the CD55 gene, which result in uncontrolled complement activation. Complement hyperactivation leads to formation of the membrane attack complex and contributes to intestinal protein loss, hypoalbuminemia, edema, and an increased risk of angiopathic thrombosis.

    Pozelimab‑bbfg (Veopoz) is a targeted anti‑C5 monoclonal antibody that inhibits cleavage of C5, preventing downstream complement activity; the clinical criteria in this policy require genetic confirmation of CD55 deficiency and clinical findings attributable to CHAPLE (for example, hypoalbuminemia and edema) to establish medical necessity.

    Policy Summary
    Payersierra health and life
    PolicyVeopoz (pozelimab‑bbfg) — Coverage Criteria
    Policy CodePolicy 2026D0128E
    Change TypeNo material change
    Effective DateMay 1, 2026
    Next Review Date
    Key ActionObtain prior authorization with genetic confirmation of a biallelic CD55 loss‑of‑function mutation and documentation of CHAPLE signs/symptoms.
    SourceLink
    On This Page
    Coverage criteria and usage restrictionsBilling and diagnosis codesPrior authorization, documentation, and denial triggersInitial authorization criteriaCriteria for continued coverageStep therapy and prerequisitesAdministration site considerationsDefinitions used in this policyClinical background
    Step Therapy

    No step therapy; concomitant C5 inhibitors prohibited

    No step‑therapy requirements are specified in this policy. Do not co‑administer Veopoz with other complement C5 inhibitors — concomitant use with agents such as eculizumab or ravulizumab for CHAPLE is prohibited.

    • Policy lists no required prior failure of alternative therapies (no step therapy)
    • Concomitant use with C5 inhibitors (e.g., eculizumab, Ultomiris/ravulizumab) is explicitly excluded
    Documentation Required

    Provide medical records confirming genetic diagnosis and baseline/follow‑up labs

    Submit complete medical records to support the authorization request, including chart notes and laboratory values that confirm a biallelic CD55 loss‑of‑function mutation and provide baseline and follow‑up data documenting CHAPLE signs/symptoms and treatment response; include documentation of the specialist prescriber (hematologist or other CHAPLE expert).

    • Genetic test results confirming biallelic CD55 loss‑of‑function mutation
    • Baseline laboratory values (e.g., serum albumin) and relevant follow‑up labs
    • Clinical notes documenting CHAPLE signs/symptoms (edema, abdominal pain, diarrhea, etc.) and response to therapy
    • Prescriber specialty and evidence of CHAPLE expertise
    Denial Risk

    Denial triggers: missing genetics, concomitant C5 inhibitor, or noncompliance with dosing/prescriber/authorization rules

    Coverage may be denied if requested documentation does not confirm a biallelic loss‑of‑function mutation in CD55, if the patient is receiving Veopoz together with another complement C5 inhibitor (e.g., eculizumab, ravulizumab), or if dosing, prescriber specialty, or authorization duration requirements are not met.

    • Absence of genetic confirmation of biallelic CD55 mutation
    • Concomitant administration of Veopoz with another C5 inhibitor
    • Non‑compliant dosing relative to FDA labeling, inappropriate prescriber specialty, or authorization requests exceeding the 12‑month initial limit